Loading organizations...
Based in Essen, Germany, Abalos Therapeutics is a biotechnology company that develops arenavirus-based immuno-oncology therapeutics designed to target and destroy solid tumors. The organization utilizes its proprietary Fast Evolution Platform to generate optimized virus variants, leveraging the lymphocytic choriomeningitis virus to preferentially infect cancer cells and trigger anti-tumor immune responses. The pre-clinical enterprise has raised a total of €43 million in Series A venture capital funding across multiple tranches, alongside a €1.2 million government grant from KMU-innovativ. This financial backing was secured from a syndicate of institutional investors that includes Boehringer Ingelheim Venture Fund, Novartis Venture Fund, Seventure Partners, and Droia Ventures. The firm recently presented preclinical efficacy data for its lead candidate at the American Association for Cancer Research. Abalos Therapeutics was founded in 2019 by immunologists Karl Lang and Philipp Lang.
Abalos Therapeutics has raised $49.2M across 2 funding rounds.
Abalos Therapeutics has raised $49.2M in total across 2 funding rounds.
Abalos Therapeutics has raised $49.2M in total across 2 funding rounds.
Abalos Therapeutics's investors include Seventure Partners, Coparion, Boehringer Ingelheim, Gründerfonds Ruhr, High-Tech Grunderfonds, Hx Bio Ventures, NRW.BANK, Ventura BioMed Investors, Dr. Aristotelis Nastos, Frank Hensel.
Abalos Therapeutics is a German biotechnology company developing novel anti-cancer therapies using a proprietary Adapt Innate platform based on arenaviruses to trigger comprehensive immune responses against solid tumors and metastases.[1][2] Their lead candidate, ABX-001, is a systemically administered, non-oncolytic immunotherapy that persists in cancer and antigen-presenting cells, engaging both innate and adaptive immunity to uncloak tumors without destroying healthy cells; it dosed its first patient in a Phase 1 trial for solid tumors in October 2025.[1][3] The company serves oncology patients by addressing immunotherapy resistance, with strong preclinical data published in Cell Reports Medicine and plans for a pipeline of naturally optimized and payload-carrying therapeutics.[1][3]
Founded in 2019, Abalos has raised €43 million in Series A funding and achieved key milestones like appointing experienced executives and securing German government funding, positioning it for clinical advancement amid rising demand for innovative cancer immunotherapies.[2][3]
Abalos Therapeutics launched in October 2019 with a €12 million Series A round to pioneer immuno-virotherapies against cancer, leveraging arenaviruses' immunostimulatory properties.[1][3] The founding team comprises experienced entrepreneurs and scientists focused on reactivating the full immune system against solid tumors, building on proprietary technology to create a new class of product candidates.[1] Early traction included expanding the leadership team with drug development and viral therapy experts in February 2020, followed by a Series A extension in 2021 totaling €43 million.[3] Pivotal moments encompass appointing Thomas Bogenrieder as Chief Medical Officer in 2022, securing KMU-innovativ funding from Germany's Federal Ministry of Education and Research in 2024, and naming Gerben Moolhuizen as CEO in October 2024.[3]
Abalos rides the cancer immunotherapy wave, particularly the shift toward viral-based platforms that address limitations of checkpoint inhibitors and CAR-T therapies by inducing broad, durable responses in "cold" solid tumors.[1][3] Timing aligns with surging investment in immuno-oncology—post-2020 funding booms and regulatory nods for viral therapies—bolstered by market forces like aging populations and unmet needs in metastatic cancers.[1][2] By validating arenavirus approaches in peer-reviewed studies and combinations, Abalos influences the ecosystem, potentially expanding virotherapy adoption and fostering synergies with T-cell engagers or payloads.[1][3]
Abalos is poised for Phase 1 readouts in 2026, with events like CICON 2025 showcasing data to partners and investors; pipeline expansion into payload-carrying candidates could accelerate toward later-stage trials.[1][3] Trends like AI-optimized viruses and combo immunotherapies will shape its path, amplifying impact as resistance mechanisms are cracked. Its evolution from startup to clinical player underscores biotech's high-stakes innovation, delivering on the promise of systemic tumor uncloaking for broader patient access.[1][3]
Abalos Therapeutics has raised $49.2M across 2 funding rounds. Most recently, it raised $36.0M Series A in October 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Oct 1, 2021 | $36M Series A | Seventure Partners | Coparion, Boehringer Ingelheim, Gründerfonds Ruhr, High Tech Grunderfonds, HX BIO Ventures, NRW.BANK, Ventura BioMed Investors | Announced |
| Oct 15, 2019 | $13.2M Series A | Boehringer Ingelheim, DR. Aristotelis Nastos | Frank Hensel, NRW.BANK | Announced |